Abstract 1337P
Background
Dacomitinib, a second-generation, irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), provided statistically significant progression-free survival improvement over gefitinib in treatment-naive patients with advanced EGFR mutation–positive non-small cell lung cancer (NSCLC) in a global phase 3 study (ARCHER 1050; NCT01774721). Here, we report interim analysis of ARIA, a non-interventional study of dacomitinib’s real-world (RW) utilization and associated clinical outcomes in Asian patients with advanced EGFR mutation–positive NSCLC.
Methods
This longitudinal, multicenter cohort study collected prospective and retrospective data from patients with advanced EGFR mutation–positive NSCLC who were treated with first-line (1L) dacomitinib based on routine practices and their best interest. Study objectives were to describe patient demographics and clinical characteristics, treatment patterns of dacomitinib use, and RW outcomes of 1L dacomitinib.
Results
300 patients from China (n=262), India (n=24), and Malaysia (n=14) were enrolled and included in the analysis. Starting dose was 30 mg once daily (QD) in 159 patients (53%), 45 mg QD in 138 (46%), and other doses in 3 (1%). As of Jan 31, 2023, 81 patients (27.0%) had dose decreases, 13 (4.3%) dose increases, 35 (11.7%) interruptions, and 107 (35.7%) permanently discontinued dacomitinib. Six (2.0%) permanent treatment discontinuations were due to treatment-related toxicities. 1L dacomitinib safety and treatment outcomes are shown in the table. Table: 1337P
Safety and treatment outcomes of 1L dacomitinib
ITT population | Total (N=300) |
Duration of 1L dacomitinib treatment, median (IQR), months | 13.1 (11.8) |
Patients with any TRAEs, n (%) | 121 (40.3) |
Most common TRAEs, n (%) | |
Rash | 74 (24.7) |
Diarrhea | 65 (21.7) |
Paronychia | 43 (14.3) |
TTF, median (95% CI), a months | 21.4 (17.3-35.9) |
rwPFS, median (95% CI), a months | 25.3 (20.1-NR) |
1L, first line; IQR, interquartile range; ITT, intention to treat; NR, not reached; rwPFS, real-world progression-free survival; TRAE, treatment-related adverse event; TTF, time to treatment failure. a Calculated using the Kaplan-Meier method to obtain 95% confidence interval.
Conclusions
To our knowledge, this is the largest RW study conducted for dacomitinib. Interim analysis shows efficacy of 1L dacomitinib; safety data in the RW setting were generally consistent with dacomitinib’s known safety profile. These results support 1L dacomitinib use in patients with advanced EGFR mutation–positive NSCLC.
Clinical trial identification
NCT04609319.
Editorial acknowledgement
Medical writing support was provided by Arrianna Carey, PhD, of ClinicalThinking, Inc, and funded by Pfizer.
Legal entity responsible for the study
Pfizer.
Funding
Pfizer.
Disclosure
L. Wu: Financial Interests, Personal, Principal Investigator: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, BMS, MSD, Roche; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, BMS, MSD, Roche. J. Li: Non-Financial Interests, Institutional, Principal Investigator: Pfizer. C. Xu: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol Myers Squibb, MSD, Novartis, Pfizer, Roche, Hengrui Pharmaceutical, BeiGene, Takeda, Burning Rock Biotech, Zhengda Tianqing Pharmaceutical Group, CStone Pharmaceuticals, Innovent Biologics; Financial Interests, Institutional, Research Grant: Hengrui Pharmaceutical, Pfizer. K. Tang: Non-Financial Interests, Institutional, Principal Investigator: The First Affiliated Hospital of Sun Yat-sen University. H. Wang: Non-Financial Interests, Institutional, Principal Investigator: Pfizer. G.F. Ho: Financial Interests, Personal, Advisory Board: Merck & Co., Inc., Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Pfizer, Merck & Co., Inc., Novartis, Roche, Boehringer Ingelheim, MSD, F. Hoffmann-La Roche AG, Eisai; Financial Interests, Personal, Other, Chairperson: Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Eli Lilly, Regeneron, Merck & Co., Inc., AB Science, Astellas, Tessa Therapeutics, Roche, Arcus Bioscience, AstraZeneca, Pfizer, Janssen Research & Development, Mirati Therapeutics, Novartis, Amgen, Boehringer Ingelheim; Non-Financial Interests, Institutional, Product Samples: Eli Lilly, Janssen Pharmaceuticals, Novartis, Pfizer, Taiho; Non-Financial Interests, Personal, Training: MSD, Ipsen, AstraZeneca, Bristol Myers Squibb, Regeneron Pharmaceuticals, Dr Reddy’s. Y. Lu: Financial Interests, Personal, Advisory Board: Pfizer. M. Zhao: Financial Interests, Personal, Principal Investigator: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Pfizer. L.M. Tho: Non-Financial Interests, Personal and Institutional, Invited Speaker: Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Merck . J. Zhao: Financial Interests, Personal, Principal Investigator: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Pfizer. S. He: Financial Interests, Personal, Other, Employment: Pfizer. J. Huang: Financial Interests, Institutional, Full or part-time Employment: Pfizer (China) Research and Development Co., Ltd. X. Tang: Financial Interests, Personal, Full or part-time Employment: Pfizer. C.H. Wong: Financial Interests, Institutional, Full or part-time Employment, Employee of Pfizer Inc: Pfizer Inc; Financial Interests, Institutional, Stocks/Shares: Pfizer Inc. Y. Wu: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Hengrui, Merk, MSD, Pfizer, Roche, Sanofi; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Takeda; Financial Interests, Coordinating PI: AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, Merk, MSD, Pfizer, Roche, Eli Lilly; Financial Interests, Steering Committee Member: Sanofi, Yunhan; Non-Financial Interests, Leadership Role: Chinese Thoracic Oncology Group (CTONG); Non-Financial Interests, Other, WCLC 2020 Conference Chair: IASLC; Non-Financial Interests, Leadership Role, Past President: Chinese Society of Clinical Oncology (CSCO). All other authors have declared no conflicts of interest.
Resources from the same session
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Presenter: Bilal Krayim
Session: Poster session 19
1344P - A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
Presenter: Jorge Nieva
Session: Poster session 19
1345P - Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
Presenter: Melissa Junttila
Session: Poster session 19
1346P - Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
Presenter: Xiaoyan Li
Session: Poster session 19
1348P - Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Presenter: Yun-Gyoo Lee
Session: Poster session 19
1349P - Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Presenter: Molly Li
Session: Poster session 19
1350P - Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
Presenter: Takehiro Tozuka
Session: Poster session 19
1351P - Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Presenter: Dan Tao
Session: Poster session 19
1352P - Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC
Presenter: Ruyun Gao
Session: Poster session 19